Key opportunities in the B-cell inhibitors market for non-oncology diseases include the rising demand for targeted immunomodulatory therapies, driven by increasing autoimmune disorder prevalence.

BTK inhibitor monotherapy is foundational across several B-cell malignancies, with newer, more selective agents designed to preserve efficacy while improving tolerability relative to first-in-class ...

AbbVie’s model based fair value has been adjusted only slightly, moving from US$248.29 to US$248.86, which keeps the overall price target essentially stable in dollar terms. That small change sits ...

Ascentage Pharma will host a Chinese (Mandarin) language investor webcast at 10:00 pm EDT on March 25, 2026 / 10:00 am HKT on March 26, 2026. To access the Chinese language investor event or ...

“The full end-to-end clinical pathway - from blood draw at a collection site through to result delivery to the ordering clinician - has now been successfully completed in a routine clinical setting,” ...

Jamie Campbell has been announced as guest speaker for 2026 Federation of Northern Ontario Municipalities conference ...